A Phase 2 interventional study of Immune Globulin IV [Human], 10% Caprylate/Chromatography Purified and Albumin (Human) 25%, United States Pharmacopeia (USP) in Multiple Sclerosis, Relapsing-Remitting, sponsored by Grifols Therapeutics LLC. Completed at 37 sites in 12 countries. Open to participants aged 18 Years to 55 Years. Per ClinicalTrials.gov, last updated 2016-04-27.
Sponsored by Grifols Therapeutics LLC (part of Grifols) · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 106 studies in Multiple Sclerosis, Relapsing-Remitting with a site in Germany — 4 open to participants now, 9 under way, 5 of them phase 3. Multiple Sclerosis, Relapsing-Remitting · Germany.
Among the 106 studies in Multiple Sclerosis, Relapsing-Remitting with a site in Germany, this one is the 58th largest by enrollment of the 87 interventional ones that give a count, is one of 2 that started in 2002, is one of 27 in phase 2, and was the 6th registered.
618 studies on the registry are indexed under Multiple Sclerosis, Relapsing-Remitting; 83 are open to participants now.
Browse Multiple Sclerosis, Relapsing-Remitting studies →4 of the 106 studies in Multiple Sclerosis, Relapsing-Remitting with a site in Germany are open now. Recruiting first, the newest first:
Heinrich-Heine University, Duesseldorf · Sites in Germany
Ages 18–79 · Healthy volunteers
Technical University of Munich · Sites in Germany
Ages 18–60 · Healthy volunteers
Universität Münster · Sites in Germany
Ages 18–60
Heinrich-Heine University, Duesseldorf · Sites in Germany
Ages 18–60
A study can be open while its sites in Germany have not opened yet or have stopped. Only those recruiting at a site in Germany →
Of the 61 Multiple Sclerosis, Relapsing-Remitting studies recruiting now, 11 (18%) set no upper age limit and 44 (72%) stop at 75 or younger; 2 take children under 18; 11 take healthy volunteers.
This study: 18 Years to 55 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
106 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 4 · Phase 2 28 · Phase 3 35 · Phase 4 14
First in 2001; this study’s year is marked. 2 started in 2002.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 128 is above the median of 66 across 437 interventional studies indexed under Multiple Sclerosis, Relapsing-Remitting.
Median enrollment 214 across the 87 interventional studies, 318 across the 19 observational. Of the 90 that completed or were terminated, 51 (57%) have results posted.
This tab as a report to print or save as PDF → With an account.
82 of 106 have an industry lead sponsor. The 10 most frequent:
This study is registered under Grifols Therapeutics LLC, one of the names counted as Grifols. Under that name alone:
Grifols Therapeutics LLC is the lead sponsor of 46 studies on the registry; 4 are open to participants now.
Of its 13 completed or terminated interventional studies of FDA-regulated products, 13 (100%) have results posted.
Grifols has 1 study filed under Multiple Sclerosis, Relapsing-Remitting — fewer than ten, so there is no comparison to draw.
4 of the studies in Multiple Sclerosis, Relapsing-Remitting with a site in Germany that are under way reach primary completion within a year, 3 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05201638Phase 3Immunic AGStudy to Evaluate the Efficacy, Safety and Tolerability of IMU-838 in Patients With Relapsing Multiple Sclerosis | 2026-11 |
| NCT06700343Phase 3AmgenComparison Between ABP 692 and Ocrevus® (Ocrelizumab) | 2027-04-19 |
| NCT03958877Phase 3BiogenA Study to Evaluate the Safety, Tolerability, and Efficacy of BIIB017 (Peginterferon Beta-1a) in Pediatric Participants for the Treatment of Relapsing-Remitting Multiple Sclerosis | 2027-05-20 |
| NCT06389968Technical University of MunichLight Stimulation to Improve Visual Function After Optic Neuritis in Persons with Multiple Sclerosis | 2026-12-31 |
Add all 4 to your calendar (.ics) → With an account.
Among the 106 studies in Multiple Sclerosis, Relapsing-Remitting with a site in Germany, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The trial will study 2 doses of Immune Globulin Intravenous (Human), 10% Caprylate/Chromatography Purified (IGIV-C) for the number of relapses that occur in a 1 year treatment period.
This trial is designed as a multi-national, randomized, double-blind, placebo-controlled prospective trial with three parallel groups.
One hundred twenty (120) patients, 40 per treatment arm, with relapsing-remitting (RR) multiple sclerosis will be enrolled in this trial. Eligible patients must have a diagnosis of MS as per the McDonald Criteria. In addition, patients must have a diagnosis of relapsing-remitting course of MS defined as periods of worsening of neurological function with full recovery or with sequelae and residual deficit upon recovery; periods between disease relapses characterized by lack of disease progression. Patients must also have active disease with at least 1 defined documented relapse in the last year.
During a 2 month run-in period, 2 MRIs will be performed 6 weeks apart and patients will be stratified based on the presence or absence of 1 or more Gadolinium enhancing lesions on the first MRI (Gd-enhancing lesion yes-no) and will be randomized to one of two dose regimens of IGIV-C or matching placebo. Patients will receive study drug infusions every 4 weeks for 48 weeks for a total of 12 infusions. Patients will be evaluated by MRI every 6 weeks and by clinical assessments every 3 months. A follow-up visit will occur 4 weeks after the last infusion.
The treatment groups are as follows:
For blinding purposes, at each infusion, all patients will receive a total volume of 4 ml/kg bw. For patients receiving 0.2 g/kg bw of IGIV-C, the final volume of 4 ml/kg bw will be adjusted by the addition of dextrose 5%. Placebo will be supplied as Albumin 5% or Albumin 25% and diluted with either dextrose 5% or saline to a final concentration of 0.1% albumin.
Dose adaptation will be performed for subsequent infusions in case the patient's body weight has changed > 10%. The maximum amount available per infusion will be 400 ml (8 vials) calculated for a patient with a body weight of 100 kg. The suggested initial infusion rate will be 0.02 ml/kg/min for the first 15 minutes. If there is no evidence of a hypersensitivity reaction, the infusion may be given at a slowly increasing rate over the next 30 minutes up to a maximum allowable rate of 0.08 ml/kg/min. As such, the infusion for a 70 kg patient will take approximately 1hour 15 min. The overall infusion time may have a range from 1 to 2 hours.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
NYHA class (heart failure)
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
IGIV-C 0.2 g/kg bw/infusion (2 ml/kg bw)
Drug: Immune Globulin IV [Human], 10% Caprylate/Chromatography Purified
IGIV-C 0.4 g/kg bw/infusion (4 ml/kg bw)
Drug: Immune Globulin IV [Human], 10% Caprylate/Chromatography Purified
placebo (0.1% albumin) 4 ml/kg bw/infusion
Drug: Albumin (Human) 25%, United States Pharmacopeia (USP)
Drug page: Immunoglobulins, Intravenous
Also known as: Gamunex®, IGIVnex®, Gaminex, IGIV-C, Immune Globulin Intravenous (Human) , 10%, IGIV, BAY 41-1000, TAL-05-00004, IGIV-C, 10%, IVIG, Immune Globulin (Human), 10% (IGIV), Immune Globulin Intravenous, 10% by Chromatography Process, NDC 13533-645-12, NDC 13533-645-15, NDC 13533-645-20, NDC 13533-645-24, NDC 13533-645-71
Also known as: Plasbumin®-5, Plasbumin®-25, Plasbumin®-5 (Low Aluminum), Plasbumin®-25 (Low Aluminum), Albumin (Human) 5%, USP, Albumin (Human) 25%, USP, TAL-05-00009, TAL-05-00023, TAL-05-00025, TAL-05-00026, BAY 34-9255, NDC 13533-684-16, NDC 13533-684-25, NDC 13533-684-71, NDC 13533-685-20, NDC 13533-685-25, NDC 13533-685-27, NDC 13533-690-20, NDC 13533-690-25, NDC 13533-690-27, NDC 13533-692-16, NDC 13533-692-20, NDC 13533-692-71
Percentage of Relapse Free Subjects (no Relapse)
A relapse was defined for the purposes of this study as the appearance or reappearance of one or more neurological symptoms or worsening of an old symptom attributed to multiple sclerosis (MS) persisting for at least 48 hours and immediately preceded by a relatively stable or improving neurological state of at least 30 days.
Time frame: 12 months
Effect on the Combined Unique Lesion Activity on Magnetic Resonance Imaging (MRI)
Time frame: 1 year
The study was conducted in 31 study centers in Austria, Canada, Czech Republic, Germany, United Kingdom, Greece, Hungary, Israel, Poland, and the United States.
| Milestone | IGIV-C 0.2 g/kg bw/Infusion (2 mL/kg Body Weight) | IGIV-C 0.4 g/kg bw/Infusion (4 mL/kg Body Weight) | Placebo (0.1% Albumin) 4 mL/kg Body Weight/Infusion |
|---|---|---|---|
| Started | 45 | 42 | 41 |
| Completed | 38 | 38 | 37 |
| Not completed | 7 | 4 | 4 |
| Withdrew: Adverse event | 1 | 0 | 0 |
| Withdrew: Withdrawal by subject | 1 | 4 | 1 |
| Withdrew: Non-compliance | 1 | 0 | 0 |
| Withdrew: Too time consuming | 1 | 0 | 0 |
| Withdrew: Pregnancy | 0 | 0 | 2 |
| Withdrew: Lack of efficacy | 3 | 0 | 1 |
Results for this outcome have not been posted.
A relapse was defined for the purposes of this study as the appearance or reappearance of one or more neurological symptoms or worsening of an old symptom attributed to multiple sclerosis (MS) persisting for at least 48 hours and immediately preceded by a relatively stable or improving neurological state of at least 30 days.
| percentage of participants | IGIV-C 0.2 g/kg bw/Infusion (2 mL/kg bw) | IGIV-C 0.4 g/kg bw/Infusion (4 mL/kg bw) | Placebo (0.1% Albumin) 4 mL/kg bw/Infusion |
|---|---|---|---|
| No Relapse | 56.8 | 59.5 | 68.3 |
| At Least One Relapse | 43.2 | 40.5 | 31.7 |
Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| IGIV-C 0.2 g/kg bw/Infusion (2 mL/kg bw) | — | 2/45 (4.4%) | 32/45 (71.1%) |
| IGIV-C 0.4 g/kg bw/Infusion (4 mL/kg bw) | — | 2/42 (4.8%) | 26/42 (61.9%) |
| Placebo (0.1% Albumin) 4 mL/kg bw/Infusion | — | 1/41 (2.4%) | 29/41 (70.7%) |
| Event | IGIV-C 0.2 g/kg bw/Infusion (2 mL/kg bw) | IGIV-C 0.4 g/kg bw/Infusion (4 mL/kg bw) | Placebo (0.1% Albumin) 4 mL/kg bw/Infusion |
|---|---|---|---|
| ToothacheGeneral disorders | 0/45 | 0/42 | 1/41 |
| Vasculitis, peripheralVascular disorders | 0/45 | 1/42 | 0/41 |
| Panic attacksPsychiatric disorders | 0/45 | 1/42 | 0/41 |
| HeadacheGeneral disorders | 1/45 | 0/42 | 0/41 |
| Herpes Zoster ophthalmicEye disorders | 1/45 | 0/42 | 0/41 |
| Event | IGIV-C 0.2 g/kg bw/Infusion (2 mL/kg bw) | IGIV-C 0.4 g/kg bw/Infusion (4 mL/kg bw) | Placebo (0.1% Albumin) 4 mL/kg bw/Infusion |
|---|---|---|---|
| NasopharyngitisInfections and infestations | 9/45 | 7/42 | 11/41 |
| RhinitisInfections and infestations | 3/45 | 7/42 | 4/41 |
| HeadacheNervous system disorders | 7/45 | 5/42 | 6/41 |
| Urinary tract infectionInfections and infestations | 1/45 | 6/42 | 2/41 |
| FatigueGeneral disorders | 5/45 | 2/42 | 5/41 |
| InfluenzaInfections and infestations | 2/45 | 1/42 | 5/41 |
| Upper respiratory tract infectionInfections and infestations | 3/45 | 0/42 | 5/41 |
| NauseaGastrointestinal disorders | 2/45 | 5/42 | 0/41 |
| Back painMusculoskeletal and connective tissue disorders | 4/45 | 5/42 | 2/41 |
| Pharyngolaryngeal painRespiratory, thoracic and mediastinal disorders | 2/45 | 5/42 | 4/41 |
| Age, Categorical(Participants) | IGIV-C 0.2 g/kg bw/Infusion (2 mL/kg bw) | IGIV-C 0.4 g/kg bw/Infusion (4 mL/kg bw) | Placebo (0.1% Albumin) 4 mL/kg bw/Infusion | Total |
|---|---|---|---|---|
| <=18 years | 0 | 1 | 0 | 1 |
| Between 18 and 65 years | 45 | 41 | 41 | 127 |
| >=65 years | 0 | 0 | 0 | 0 |
| Age, Continuous(years) | IGIV-C 0.2 g/kg bw/Infusion (2 mL/kg bw) | IGIV-C 0.4 g/kg bw/Infusion (4 mL/kg bw) | Placebo (0.1% Albumin) 4 mL/kg bw/Infusion | Total |
|---|---|---|---|---|
| Mean | 31.9 ± 7.5 | 34.4 ± 7.9 | 33.0 ± 8.7 | 33.1 ± 8.0 |
| Sex: Female, Male(Participants) | IGIV-C 0.2 g/kg bw/Infusion (2 mL/kg bw) | IGIV-C 0.4 g/kg bw/Infusion (4 mL/kg bw) | Placebo (0.1% Albumin) 4 mL/kg bw/Infusion | Total |
|---|---|---|---|---|
| Female | 38 | 27 | 31 | 96 |
| Male | 7 | 15 | 10 | 32 |
| Region of Enrollment(participants) | IGIV-C 0.2 g/kg bw/Infusion (2 mL/kg bw) | IGIV-C 0.4 g/kg bw/Infusion (4 mL/kg bw) | Placebo (0.1% Albumin) 4 mL/kg bw/Infusion | Total |
|---|---|---|---|---|
| United States | 5 | 3 | 3 | 11 |
| Czech Republic | 6 | 10 | 6 | 22 |
| Hungary | 4 | 2 | 2 | 8 |
| Greece | 1 | 2 | 0 | 3 |
| Canada | 5 | 1 | 5 | 11 |
| Poland | 10 | 6 | 8 | 24 |
| Austria | 3 | 1 | 2 | 6 |
| Israel | 1 | 0 | 2 | 3 |
| Germany | 9 | 15 | 11 | 35 |
| United Kingdom | 1 | 2 | 2 | 5 |
The record gives a start of Dec 2002, a primary completion of Feb 2005 and a completion of Feb 2005. It does not say whether these dates are actual or estimated.
Results were first posted in Apr 2014, 9 years 2 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Mar 2016. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Immunoglobulins, Intravenous
Multiple Sclerosis, Relapsing-Remitting →